瑞银发表研究报告指，华润医药(03320.HK) 去年收入及纯利均逊于预期。该行预期集团今年的收入将有高个位数增长。由于有利的业务组合改变及创新业务的增长，预计集团今年的毛利率及净利润率将持续上扬，但应占纯利增长可能会受到MI增长的拖累。
该行下调集团2025至2027年的盈测，以反映分销业务增长放缓及少数股东权益增加，又将目标价由9.9元降至8.6元，续予“买入”评级。(sl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.